UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
||
|
Date of Report (Date of earliest event reported)
|
||
|
|
||
|
(Exact name of registrant as specified in its charter)
|
|
|
|
|
||
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
|
|
||
|
(Address of principal executive offices and zip code)
|
||
|
(
|
||
|
(Registrant’s telephone number, including area code)
|
||
|
N/A
|
||
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 |
Results of Operations and Financial Condition.
|
On May 8, 2025, Nu Skin Enterprises, Inc. (the “Company”) issued a press release announcing its financial results for the three-month period ended March 31, 2025, and
certain other information. A copy of the press release is attached as Exhibit 99.1 to this report.
The information furnished pursuant to this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
| Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits.
|
Nu Skin Enterprises’ press release dated May 8, 2025, regarding financial results for the three-month period ended March 31, 2025.
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
NU SKIN ENTERPRISES, INC.
|
||
|
(Registrant)
|
||
|
/s/ James D. Thomas
|
||
|
James D. Thomas
|
||
|
Chief Financial Officer
|
||
|
Date: May 8, 2025
|
||
Exhibit 99.1
FOR IMMEDIATE RELEASE
Nu Skin Enterprises Reports First Quarter Revenue at High End of Guidance
PROVO, Utah — May 8, 2025 — Nu Skin Enterprises Inc.
(NYSE: NUS) today announced first quarter revenue at the high end of its guidance range.
Executive Summary
Q1 2025 vs. Prior-year Quarter
|
Revenue
|
$364.5 million; (12.7)%
• (3.0)% FX impact or $(12.3) million
|
||
|
Earnings Per Share (EPS)
|
$2.14 or $0.23 excluding Mavely gain and other charges compared to $(0.01) or $0.09 excluding restructuring charges
|
||
|
Customers
|
776,712; (11)%
|
||
|
Paid Affiliates
|
131,518; (15)%
|
||
|
Sales Leaders
|
31,036; (20)%
|
“We are pleased to achieve revenue at the high end of our guidance range and exceed our adjusted earnings forecast to start out the year,” said Ryan Napierski, Nu Skin
president and CEO. “We drove year-over-year growth in Latin America and our Rhyz manufacturing segment, but we continue to experience consumer caution in premium beauty due to concerns such as inflation and tariffs in many parts of the world. Through
2025, we remain focused on building on our recent product launches and preparing for the preview of our Prysm iO intelligent wellness device in the back half of the year. This palm-sized device provides real-time insights into a customer's health,
informing recommendations for product subscriptions and increasing customer satisfaction and loyalty. We are also laying the groundwork for expansion into India with a market pre-opening in Q4 and formal launch in mid-2026 and prioritizing our
efforts to continue improving margins across the board.”
|
Nu Skin Enterprises Reports First Quarter 2025 Financial Results
|
page 2
|
Q1 2025 Year-over-year Operating Results
|
Revenue
|
$364.5 million compared to $417.3 million
• (3.0)% FX impact
or $(12.3) million
|
||
|
Gross Margin
|
67.8% compared to 70.5%
• Nu Skin business
was 76.7% compared to 76.9%
|
||
|
Selling Expenses
|
32.5% compared to 36.8%
• Nu Skin business
was 38.7% compared to 41.7%
|
||
|
G&A Expenses
|
31.1% or 28.9% excluding certain charges compared to 29.9%
|
||
|
Restructuring and Impairment Expenses
|
$25.1 million impairment compared to $7.3 million restructuring charges
|
||
|
Operating Margin
|
(2.7)% or 6.4% excluding impairment and other charges compared to 2.1% or 3.8% excluding restructuring charges
|
||
|
Interest Expense
|
$3.3 million compared to $7.3 million
|
||
|
Gain on Sale of Business
|
$176.2 million gain on sale of Mavely
|
||
|
Other Expense
|
$28.4 million compared to $0.4 million
• Reflects $28.1
million unrealized loss on investment
|
||
|
Income Tax Rate
|
20.1% or 41.9% excluding Mavely gain and other charges compared to 148.4% or 48.5% excluding restructuring charges
|
||
|
EPS
|
$2.14 or $0.23 excluding Mavely gain and other charges compared to $(0.01) or $0.09 excluding restructuring charges
|
Stockholder Value
|
Dividend Payments
|
$3.0 million
|
||
|
Stock Repurchases
|
$5.0 million
• $157.4 million
remaining in authorization
|
Q2 and Full-year 2025 Outlook
|
Q2 2025 Revenue
|
$355 to $390 million; (19)% to (11)% or (17)% to (9)% excluding Mavely 2024 revenue
• Approximately (3) to (2)% FX impact
|
||
|
Q2 2025 EPS
|
$ 0.20 to $0.30
|
||
|
2025 Revenue
|
$1.48 to $1.62 billion; (15)% to (6)% or (11)% to (3)% excluding Mavely 2024 revenue
• Approximately (3)% FX impact
|
||
|
2025 EPS
|
$2.80 to $3.20 or $0.90 to $1.30 excluding Mavely gain and other charges
|
|
Nu Skin Enterprises Reports First Quarter 2025 Financial Results
|
page 3
|
“In addition to delivering on revenue and adjusted earnings, we saw encouraging improvement in core Nu Skin operating margin, driven by ongoing cost
efficiency initiatives across every segment,” said James D. Thomas, chief financial officer. “We also made meaningful progress in strengthening our balance sheet by reducing outstanding debt by $155 million, achieving our lowest debt level in more
than 10 years. In addition, we returned $8 million to shareholders — $3 million in the form of dividends and $5 million via share repurchases. While macroeconomic uncertainty around trade tensions and tariffs continues to impact visibility, we are
maintaining our adjusted annual guidance as we closely monitor developments throughout the remainder of 2025. For the second quarter, we project revenue between $355 million and $390 million, with earnings per share in the range of $0.20 to $0.30.”
Conference Call
The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the
webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available on the same page through May 22, 2025.
About Nu Skin Enterprises Inc.
The Nu Skin Enterprises Inc. (NYSE: NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness
company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company’s products help people look, feel and live their best with brands including Nu Skin®
personal care, Pharmanex® nutrition and ageLOC® anti-aging, which includes an award-winning line of beauty device systems. Formed in 2018, Rhyz is a synergistic ecosystem of consumer, technology and manufacturing companies focused on
innovation within the beauty, wellness and lifestyle categories.
Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the
company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s
expectations regarding the macro environment and the company’s performance, growth and growth opportunities, shareholder value, product previews and launches, investments, initiatives, and new market expansion; projections regarding revenue,
expenses, margins, tax rates, earnings per share, foreign currency fluctuations, uses of cash, financial position and other financial items; statements of belief; and
statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “anticipate,” “accelerate,” “project,” “vision,” “remain,” “continue,” “outlook,”
“guidance,” “improve,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words.
|
Nu Skin Enterprises Reports First Quarter 2025 Financial Results
|
page 4
|
The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially
from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:
| • |
any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a
sustained basis;
|
| • |
risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner
that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions,
imposition of fines, or any other adverse actions or events;
|
| • |
economic conditions and events globally;
|
| • |
the company’s future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the company’s products imported into the company’s markets, and
any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets;
|
| • |
competitive pressures in the company’s markets;
|
| • |
risk that epidemics or other crises, as well as any related disruptions, could negatively impact our business;
|
| • |
adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;
|
| • |
political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;
|
| • |
uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business
operations and results;
|
| • |
risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;
|
| • |
uncertainties regarding the future financial performance of the businesses the company has acquired;
|
| • |
risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of
inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies; and
|
| • |
regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a
market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements.
|
The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated
risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no duty
to update the forward-looking statements contained in this release to reflect any change except as required by law.
Non-GAAP Financial Measures:
Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by
translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that constant-currency revenue
change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period.
|
Nu Skin Enterprises Reports First Quarter 2025 Financial Results
|
page 5
|
Earnings per share, general & administrative expenses, operating margin and income tax rate, each excluding the gain from the Mavely sale,
restructuring charges, impairment charges, and/or other charges, as well as revenue growth rate excluding Mavely 2024 revenue, also are non-GAAP financial measures.
| • |
Restructuring charges and impairment charges are not part of the ongoing operations of our underlying business;
|
| • |
Mavely revenue is no longer included in our operations following our sale of this business on January 2, 2025; and
|
| • |
the gain from the Mavely sale and the other charges incurred in connection with this sale that have been excluded in the non-GAAP financial measures are not typical for our
ongoing operations.
|
The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these items
facilitates period-to-period comparisons of the company’s performance. Please see the reconciliations of these items to our earnings per share, general & administrative expenses, operating margin, income tax rate and revenue growth rate
calculated under GAAP, below.
The following table sets forth revenue for the three-month periods ended March 31, 2025, and 2024 for each of our reportable segments (U.S. dollars in thousands):
|
Three Months Ended
March 31,
|
Constant-Currency
|
|||||||||||||||
|
2025
|
2024
|
Change
|
Change
|
|||||||||||||
|
Nu Skin
|
||||||||||||||||
|
Americas
|
$
|
69,058
|
$
|
75,031
|
(8.0
|
)%
|
(1.3
|
)%
|
||||||||
|
Southeast Asia/Pacific
|
52,172
|
60,065
|
(13.1
|
)%
|
(12.0
|
)%
|
||||||||||
|
Mainland China
|
47,775
|
61,067
|
(21.8
|
)%
|
(20.6
|
)%
|
||||||||||
|
Japan
|
42,765
|
44,236
|
(3.3
|
)%
|
(0.8
|
)%
|
||||||||||
|
Europe & Africa
|
33,021
|
42,273
|
(21.9
|
)%
|
(19.5
|
)%
|
||||||||||
|
South Korea
|
32,515
|
40,963
|
(20.6
|
)%
|
(13.3
|
)%
|
||||||||||
|
Hong Kong/Taiwan
|
28,447
|
30,466
|
(6.6
|
)%
|
(4.0
|
)%
|
||||||||||
|
Other
|
529
|
672
|
(21.3
|
)%
|
(21.3
|
)%
|
||||||||||
|
Total Nu Skin
|
306,282
|
354,773
|
(13.7
|
)%
|
(10.2
|
)%
|
||||||||||
|
Rhyz
|
||||||||||||||||
|
Manufacturing
|
55,290
|
50,302
|
9.9
|
%
|
9.9
|
%
|
||||||||||
|
Rhyz other
|
2,918
|
12,231
|
(76.1
|
)%
|
(76.1
|
)%
|
||||||||||
|
Total Rhyz
|
58,208
|
62,533
|
(6.9
|
)%
|
(6.9
|
)%
|
||||||||||
|
Total
|
$
|
364,490
|
$
|
417,306
|
(12.7
|
)%
|
(9.7
|
)%
|
||||||||
|
Nu Skin Enterprises Reports First Quarter 2025 Financial Results
|
page 6
|
The following table provides information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods
ended March 31, 2025, and 2024:
|
Three Months Ended
March 31,
|
||||||||||||
|
2025
|
2024
|
Change
|
||||||||||
|
Customers
|
||||||||||||
|
Americas
|
227,514
|
199,399
|
14
|
%
|
||||||||
|
Southeast Asia/Pacific
|
74,584
|
93,411
|
(20
|
)%
|
||||||||
|
Mainland China
|
122,474
|
162,239
|
(25
|
)%
|
||||||||
|
Japan
|
107,742
|
108,808
|
(1
|
)%
|
||||||||
|
Europe & Africa
|
130,154
|
163,481
|
(20
|
)%
|
||||||||
|
South Korea
|
71,721
|
100,230
|
(28
|
)%
|
||||||||
|
Hong Kong/Taiwan
|
42,523
|
47,693
|
(11
|
)%
|
||||||||
|
Total Customers
|
776,712
|
875,261
|
(11
|
)%
|
||||||||
|
Paid Affiliates
|
||||||||||||
|
Americas
|
26,936
|
29,081
|
(7
|
)%
|
||||||||
|
Southeast Asia/Pacific
|
22,296
|
29,778
|
(25
|
)%
|
||||||||
|
Mainland China
|
19,859
|
24,405
|
(19
|
)%
|
||||||||
|
Japan
|
21,073
|
21,679
|
(3
|
)%
|
||||||||
|
Europe & Africa
|
15,184
|
18,313
|
(17
|
)%
|
||||||||
|
South Korea
|
16,548
|
20,594
|
(20
|
)%
|
||||||||
|
Hong Kong/Taiwan
|
9,622
|
10,321
|
(7
|
)%
|
||||||||
|
Total Paid Affiliates
|
131,518
|
154,171
|
(15
|
)%
|
||||||||
|
Sales Leaders
|
||||||||||||
|
Americas
|
6,174
|
6,616
|
(7
|
)%
|
||||||||
|
Southeast Asia/Pacific
|
4,542
|
5,570
|
(18
|
)%
|
||||||||
|
Mainland China
|
6,214
|
9,600
|
(35
|
)%
|
||||||||
|
Japan
|
6,210
|
6,385
|
(3
|
)%
|
||||||||
|
Europe & Africa
|
2,839
|
3,715
|
(24
|
)%
|
||||||||
|
South Korea
|
2,850
|
4,122
|
(31
|
)%
|
||||||||
|
Hong Kong/Taiwan
|
2,207
|
2,601
|
(15
|
)%
|
||||||||
|
Total Sales Leaders
|
31,036
|
38,609
|
(20
|
)%
|
||||||||
| ● |
“Customers” are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our sales force who made such a
purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.
|
| ● |
“Paid Affiliates” are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides
Mainland China, we refer to members of our independent sales force as “Brand Affiliates” because their primary role is to promote our brand and products through their personal social networks.
|
| ● |
“Sales Leaders” are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements as
of the end of each month of the quarter.
|
|
Nu Skin Enterprises Reports First Quarter 2025 Financial Results
|
page 7
|
NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
(U.S. dollars in thousands, except per share amounts)
|
Three Months Ended
March 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
Revenue
|
$
|
364,490
|
$
|
417,306
|
||||
|
Cost of sales
|
117,529
|
123,242
|
||||||
|
Gross profit
|
246,961
|
294,064
|
||||||
|
Operating expenses:
|
||||||||
|
Selling expenses
|
118,546
|
153,542
|
||||||
|
General and administrative expenses
|
113,204
|
124,566
|
||||||
|
Restructuring and impairment expenses
|
25,114 |
7,134 |
||||||
|
Total operating expenses
|
256,864
|
285,242
|
||||||
|
Operating income (loss)
|
(9,903
|
)
|
8,822
|
|||||
|
Interest expense
|
3,283
|
7,325
|
||||||
|
Gain on sale of business
|
176,162
|
—
|
||||||
|
Other expense, net
|
(28,375
|
)
|
(396
|
)
|
||||
|
Income before provision for income taxes
|
134,601
|
1,101
|
||||||
|
Provision for income taxes
|
27,086
|
1,634
|
||||||
|
Net income (loss)
|
$
|
107,515
|
$
|
(533
|
)
|
|||
|
Net income (loss) per share:
|
||||||||
|
Basic
|
$
|
2.16
|
$
|
(0.01
|
)
|
|||
|
Diluted
|
$
|
2.14
|
$
|
(0.01
|
)
|
|||
|
Weighted-average common shares outstanding (000s):
|
||||||||
|
Basic
|
49,764
|
49,538
|
||||||
|
Diluted
|
50,328
|
49,538
|
||||||
|
Nu Skin Enterprises Reports First Quarter 2025 Financial Results
|
page 8
|
NU SKIN ENTERPRISES, INC.
Consolidated Balance Sheets (Unaudited)
(U.S. dollars in thousands)
|
March 31,
2025
|
December 31,
2024
|
|||||||
|
ASSETS
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
203,770
|
$
|
186,883
|
||||
|
Current investments
|
9,781
|
11,111
|
||||||
|
Accounts receivable, net
|
56,576
|
50,784
|
||||||
|
Inventories, net
|
188,776
|
190,242
|
||||||
|
Prepaid expenses and other
|
65,954
|
72,643
|
||||||
|
Current assets held for sale
|
—
|
26,936
|
||||||
|
Total current assets
|
524,857
|
538,599
|
||||||
|
Property and equipment, net
|
380,067
|
379,595
|
||||||
|
Operating lease right-of-use assets
|
79,389
|
72,605
|
||||||
|
Goodwill
|
83,625
|
83,625
|
||||||
|
Other intangible assets, net
|
47,554
|
74,278
|
||||||
|
Other assets
|
275,919
|
298,008
|
||||||
|
Long-term assets held for sale
|
—
|
22,204
|
||||||
|
Total assets
|
$
|
1,391,411
|
$
|
1,468,914
|
||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
33,590
|
$
|
34,880
|
||||
|
Accrued expenses
|
206,710
|
217,808
|
||||||
|
Current portion of long-term debt
|
20,000
|
30,000
|
||||||
|
Current liabilities held for sale
|
—
|
13,919
|
||||||
|
Total current liabilities
|
260,300
|
296,607
|
||||||
|
Operating lease liabilities
|
61,949
|
58,439
|
||||||
|
Long-term debt
|
218,757
|
363,613
|
||||||
|
Other liabilities
|
96,436
|
97,475
|
||||||
|
Long-term liabilities held for sale
|
—
|
1,325
|
||||||
|
Total liabilities
|
637,442
|
817,459
|
||||||
|
Commitments and contingencies
|
||||||||
|
Stockholders’ equity:
|
||||||||
|
Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued
|
91
|
91
|
||||||
|
Additional paid-in capital
|
623,477
|
627,787
|
||||||
|
Treasury stock, at cost – 41.2 million and 40.8 million shares
|
(1,562,211
|
)
|
(1,563,614
|
)
|
||||
|
Accumulated other comprehensive loss
|
(123,850
|
)
|
(124,758
|
)
|
||||
|
Retained earnings
|
1,8416,462
|
1,711,949
|
||||||
|
Total stockholders' equity
|
753,969
|
651,455
|
||||||
|
Total liabilities and stockholders’ equity
|
$
|
1,391,411
|
$
|
1,468,914
|
||||
|
Nu Skin Enterprises Reports First Quarter 2025 Financial Results
|
page 9
|
NU SKIN ENTERPRISES, INC.
Reconciliation of General and Administrative Expenses Excluding Certain Charges to GAAP General and Administrative Expenses
(in thousands, except for per share amounts)
|
Three months ended
March 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
General and administrative expenses
|
$
|
113,204
|
$
|
124,566
|
||||
|
Impact of other charges(1)
|
(7,966
|
)
|
-
|
|||||
|
Adjusted general and administrative expenses
|
$
|
105,238
|
$
|
124,566
|
||||
|
General and administrative expenses as a percentage of revenue
|
31.1
|
%
|
29.9
|
%
|
||||
|
General and administrative expenses as a percentage of revenue, excluding certain charges
|
28.9
|
%
|
29.9
|
%
|
||||
|
Revenue
|
$
|
364,490
|
$
|
417,306
|
||||
(1) Other charges for the first quarter of 2025 consist of expenses incurred in connection with the Mavely sale, including $2.7 million of transaction
bonuses for certain employees and $5.2 million of equity compensation as a result of the vesting of the Mavely profits interest units.
NU SKIN ENTERPRISES, INC.
Reconciliation of Operating Margin Excluding Certain Charges to GAAP Operating Margin
(in thousands, except for per share amounts)
|
Three months ended
March 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
Operating Income (loss)
|
$
|
(9,903
|
)
|
$
|
8,822
|
|||
|
Impact of other charges(1)
|
7,966
|
-
|
||||||
|
Impact of restructuring and impairment
|
25,114
|
7,134
|
||||||
|
Adjusted operating income
|
$
|
23,177
|
$
|
15,956
|
||||
|
Operating margin
|
(2.7
|
)%
|
2.1
|
%
|
||||
|
Operating margin, excluding certain charges
|
6.4
|
%
|
3.8
|
%
|
||||
|
Revenue
|
$
|
364,490
|
$
|
417,306
|
||||
|
Nu Skin Enterprises Reports First Quarter 2025 Financial Results
|
page 10
|
NU SKIN ENTERPRISES, INC.
Reconciliation of Effective Tax Rate Excluding Impact of Mavely Gain and Certain Charges to GAAP Effective Tax Rate
(in thousands, except for per share amounts)
|
Three months ended
March 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
Provision for income taxes
|
$
|
27,086
|
$
|
1,634
|
||||
|
Impact of other charges(1) on provision for income taxes
|
725
|
-
|
||||||
|
Impact of restructuring and impairment on provision for income taxes
|
5,433
|
2,356
|
||||||
|
Impact of gain on Mavely sale on provision for income taxes
|
(31,104
|
)
|
||||||
|
Impact of unrealized investment loss on provision for income taxes
|
6,074
|
-
|
||||||
|
Provision for income taxes, excluding impact of Mavely gain and certain charges
|
$
|
8,214
|
$
|
3,990
|
||||
|
Income before provision for income taxes
|
134,601
|
1,101
|
||||||
|
Impact of other charges(1)
|
7,966
|
-
|
||||||
|
Impact of restructuring and impairment expense:
|
25,114
|
7,134
|
||||||
|
Impact of gain on Mavely sale
|
(176,162
|
)
|
-
|
|||||
|
Impact of unrealized investment loss
|
28,077
|
-
|
||||||
|
Income before provision for income taxes, excluding impact of certain charges
|
$
|
19,596
|
$
|
8,235
|
||||
|
Effective tax rate
|
20.1
|
%
|
148.4
|
%
|
||||
|
Effective tax rate, excluding impact of certain charges
|
41.9
|
%
|
48.5
|
%
|
||||
|
Nu Skin Enterprises Reports First Quarter 2025 Financial Results
|
page 11
|
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Impact of Mavely Gain and Certain Charges to GAAP Earnings Per Share
(in thousands, except for per share amounts)
|
Three months ended
March 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
Net income (loss)
|
$
|
107,515
|
$
|
(533
|
)
|
|||
|
Impact of other charges
|
||||||||
|
Other charges(1)
|
7,966
|
-
|
||||||
|
Tax impact
|
(725
|
)
|
-
|
|||||
|
Impact of restructuring and impairment expense:
|
||||||||
|
Restructuring and impairment
|
25,114
|
7,134
|
||||||
|
Tax impact
|
(5,433
|
)
|
(2,356
|
)
|
||||
|
Impact of gain on Mavely sale
|
||||||||
|
Gain on Mavely sale
|
(176,162
|
)
|
-
|
|||||
|
Tax impact
|
31,104
|
-
|
||||||
|
Impact of unrealized investment loss
|
||||||||
|
Unrealized investment loss
|
28,077
|
-
|
||||||
|
Tax impact
|
(6,074
|
)
|
-
|
|||||
|
Adjusted net income
|
$
|
11,382
|
$
|
4,245
|
||||
|
Diluted earnings per share
|
$
|
2.14
|
$
|
(0.01
|
)
|
|||
|
Diluted earnings per share, excluding restructuring impact
|
$
|
0.23
|
$
|
0.09
|
||||
|
Weighted-average common shares outstanding (000)
|
50,328
|
49,538
|
||||||
|
Nu Skin Enterprises Reports First Quarter 2025 Financial Results
|
page 12
|
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Impact of Restructuring to GAAP Earnings
Per Share
|
Year ended December 31, 2025
|
||||||||
|
Low end
|
High end
|
|||||||
|
Earnings Per Share
|
$
|
2.80
|
$
|
3.20
|
||||
|
Impact of other charges
|
||||||||
|
Other charges(1)
|
0.16
|
0.16
|
||||||
|
Tax impact
|
(0.01
|
)
|
(0.01
|
)
|
||||
|
Impact of restructuring and impairment expense:
|
||||||||
|
Restructuring and impairment
|
0.50
|
0.50
|
||||||
|
Tax impact
|
(0.11
|
)
|
(0.11
|
)
|
||||
|
Impact of gain on Mavely sale
|
||||||||
|
Gain on Mavely sale
|
(3.50
|
)
|
(3.50
|
)
|
||||
|
Tax impact
|
0.62
|
0.62
|
||||||
|
Impact of unrealized investment loss
|
||||||||
|
Unrealized investment loss
|
0.56
|
0.56
|
||||||
|
Tax impact
|
(0.12
|
)
|
(0.12
|
)
|
||||
|
Adjusted EPS
|
$
|
0.90
|
$
|
1.30
|
||||
NU SKIN ENTERPRISES, INC.
Reconciliation of Revenue Growth Rates Excluding Mavely to GAAP Revenue Growth Rates
(in thousands)
|
Three months ended
June 30, 2025
|
Year ended
December 31, 2025
|
|||||||||||||||
|
Low end
|
High end
|
Low end
|
High end
|
|||||||||||||
|
2024 Revenue
|
$
|
439,081
|
$
|
439,081
|
$
|
1,732,084
|
$
|
1,732,084
|
||||||||
|
Less: Mavely 2024 Revenue
|
12,007
|
12,007
|
69,620
|
69,620
|
||||||||||||
|
Adjusted 2024 Revenue
|
$
|
427,074
|
$
|
427,074
|
$
|
1,662,464
|
$
|
1,662,464
|
||||||||
|
Revenue Growth Rate
|
(19
|
)%
|
(11
|
)%
|
(15
|
)%
|
(6
|
)%
|
||||||||
|
Revenue Growth Rate, excluding Mavely
|
(17
|
)%
|
(9
|
)%
|
(11
|
)%
|
(3
|
)%
|
||||||||
|
2025 Forecasted Revenue
|
$
|
355,000
|
$
|
390,000
|
$
|
1,480,000
|
$
|
1,620,000
|
||||||||
# # #
CONTACTS:
Media: media@nuskin.com, (801) 345-6397
Investors: investorrelations@nuskin.com, (801) 345-3577